IGC Pharma, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
IGC$0.20-4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except loss per share and share data)
| Three months ended | ||||
|---|---|---|---|---|
| March 31, | ||||
| 2026($) | 2025($) | |||
| Revenue | 317 | 330 | ||
| Cost of revenue | (262) | (176) | ||
| Gross profit | 55 | 154 | ||
| Selling, general, and administrative expenses | (1,241) | (570) | ||
| Research and development expenses | (1,272) | (997) | ||
| Operating loss | (2,458) | (1,413) | ||
| Other income, net | 56 | 215 | ||
| Loss before income taxes | (2,402) | (1,198) | ||
| Income tax expense/benefit | - | - | ||
| Net loss attributable to common stockholders | (2,402) | (1,198) | ||
| Foreign currency translation adjustments | (8) | 6 | ||
| Comprehensive loss | (2,410) | (1,192) | ||
| Net loss per share attributable to common stockholders: | ||||
| Basic and diluted | $(0.02) | $(0.02) | ||
| Weighted-average number of shares used in computing loss per share amounts: | 98,161,733 | 79,658,429 | ||
| March 31, 2026, Form 10-Q
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.